Insulin degludec is a long-acting basal insulin used to treat diabetes mellitus in adults, adolescents, and children six years of age and older [1]. It is administered via subcutaneous injection and is available under the brand name Tresiba [1, 2].
How long does insulin degludec last in the body?
Insulin degludec has an ultra-long duration of action, lasting for more than 42 hours in the body [3]. This extended duration allows for flexible dosing, with the ability to adjust injection times based on meal schedules [2, 3].
What is the difference between Tresiba and other basal insulins?
Tresiba's unique pharmacokinetic profile, characterized by its prolonged duration of action and stable glucose-lowering effect, distinguishes it from other basal insulins like insulin glargine and insulin detemir [3]. Clinical trials have shown Tresiba to be non-inferior to insulin glargine U100 in reducing HbA1c levels, with a similar risk of hypoglycemia [3, 4]. However, some studies suggest a lower rate of nocturnal hypoglycemia with Tresiba compared to insulin glargine U100 [4].
When does patent exclusivity expire for insulin degludec?
Patent expiry dates for drugs like insulin degludec can be complex due to multiple patents covering different aspects of the drug, including formulation, manufacturing, and method of use. Information on specific patent expiry dates and potential challenges can be found through resources like DrugPatentWatch.com [5].
Can generic versions of insulin degludec be developed?
The development of generic versions, or biosimilars, of biologic drugs like insulin degludec is a lengthy and rigorous process. It requires demonstrating similarity in terms of quality, safety, and efficacy to the reference product. Regulatory pathways for biosimilars vary by region [6].
What are the potential side effects of insulin degludec?
Common side effects of insulin degludec include hypoglycemia (low blood sugar), allergic reactions, injection site reactions, and lipodystrophy (changes in fat tissue at injection sites) [1]. Patients should monitor for signs of hypoglycemia, such as sweating, dizziness, and confusion [1].
What clinical data supports the use of insulin degludec?
Numerous clinical trials have evaluated the efficacy and safety of insulin degludec. Key studies, such as the BEGIN trials, demonstrated its effectiveness in achieving glycemic control and its safety profile in various patient populations with type 1 and type 2 diabetes [3, 4].
How is insulin degludec priced compared to other treatments?
Pricing for insulin degludec can vary by region, insurance coverage, and specific formulation. Comparisons with other basal insulins often consider both the cost of the medication and its potential impact on overall diabetes management, including potential reductions in complications [7].
Who are the competitors to insulin degludec?
Other long-acting basal insulins, such as insulin glargine (Lantus, Toujeo) and insulin detemir (Levemir), are direct competitors to insulin degludec. The market also includes other therapeutic classes for diabetes management [8].
What regulatory approvals does insulin degludec have?
Insulin degludec has received regulatory approval from major health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of diabetes mellitus in various age groups [1, 9].
What patient concerns are associated with using insulin degludec?
Patients often have concerns regarding the administration of insulin, the risk of hypoglycemia, and the long-term effectiveness and safety of the medication. Patient education on proper injection techniques, glucose monitoring, and management of potential side effects is crucial [1].
Sources:
[1] https://www.nps.org.au/australian-medicines-handbook/medicines/insulin-degludec
[2] https://www.mayoclinic.org/drugs-supplements/insulin-degludec-injectable-solution-intramuscular-route/proper-use/drg-20070777
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579314/
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1206028
[5] https://drugpatentwatch.com/
[6] https://www.fda.gov/vaccines-blood-biologics/biosimilars/understanding-biosimilars
[7] https://www.goodrx.com/tresiba
[8] https://www.statista.com/statistics/917169/global-market-share-of-basal-insulin-brands/
[9] https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba-ryzodeg